LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic?

LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic?

Saved in:

Bibliographic Details
Main Authors:	N Mallofré, G Torres, C Roca, P Rojas, M Sutil, N Casanovas, M Lloreda, F Castaldo, E Bosch, A Martínez-Rubio
Format:	Article
Language:	English
Published:	Radcliffe Medical Media 2023-04-01
Series:	European Cardiology Review
Online Access:	https://www.ecrjournal.com/articleindex/ecr.2023.18.PO2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Appropriateness of Antiplatelet Pretreatment in Non-ST-segment Elevation Acute Coronary Syndrome: Differences Between Unstable Angina and Acute Myocardial Infarction
by: G Torres-Ruiz, et al.
Published: (2023-04-01)

Preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention
by: A. M. Kochergina, et al.
Published: (2023-09-01)

Circulating Malondialdehyde-Modified LDL-Related Variables and Coronary Artery Stenosis in Asymptomatic Patients with Type 2 Diabetes
by: Kazuya Fujihara, et al.
Published: (2015-01-01)

Oxidized LDL and Risk of Coronary Heart Disease
by: Luma Abdalmunim Baker
Published: (2023-01-01)

Role of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes
by: V. N. Karetnikova, et al.
Published: (2023-01-01)

Characteristics of patients with coronary artery disease and type 2 diabetes mellitus undergoing elective percutaneous coronary intervention
by: Anastasiya G. Neeshpapa, et al.
Published: (2025-01-01)

THE INFLUENCE OF DIABETES MELLITUS ON THE COURSE AND OUTCOMES OF MYOCARDIAL INFARCTION IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS
by: B. U. Mardanov, et al.
Published: (2016-12-01)

Oxidized LDL and lipids as risk factors for ischemic heart disease in type 2 diabetes
by: Zamaklar Miroslava N., et al.
Published: (2005-01-01)

Low LDL particle levels associate with coronary arteries free from atherosclerosis in long-term type 1 diabetes: the Dialong study
by: Marte Narum, et al.
Published: (2025-07-01)

Prognostic significance of inflammatory biomarkers in diabetic and non-diabetic patients with STEMI, treated with primary percutaneous coronary intervention
by: Milić Veljko, et al.
Published: (2019-01-01)

Percutaneous coronary intervention for patients with type 2 diabetes mellitus: risks and novel way to manage
by: Anastasia M. Kochergina, et al.
Published: (2019-06-01)

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With 3‐Vessel Coronary Artery Disease and Diabetes
by: Ryaan EL‐Andari, et al.
Published: (2025-06-01)

Impact of peripheral conditioning on reperfusion injury following primary percutaneous coronary intervention in diabetic and non-diabetic STEMI patients
by: Andric Veljko, et al.
Published: (2025-04-01)

The Role of Endothelin‐1, Kidney Function and Diabetes in Patients With Coronary Artery Disease Underwent Percutaneous Coronary Intervention
by: Zixiang Ye, et al.
Published: (2025-07-01)

Argan Oil Exerts an Antiatherogenic Effect by Improving Lipids and Susceptibility of LDL to Oxidation in Type 2 Diabetes Patients
by: M. M. Ould Mohamedou, et al.
Published: (2011-01-01)

Association of baseline remnant cholesterol independent of LDL-cholesterol with newly diagnosed diabetes in the Chinese population
by: Yulu Yang, et al.
Published: (2024-10-01)

Evidence-based Management of Left Main Coronary Artery Disease
by: Gabriel Torres-Ruiz, et al.
Published: (2023-12-01)

Pharmacologic Cardiac Stress (PS-SPECT): Still Valuable for Prognosis in Chronic Coronary Syndrome
by: Núria Mallofré
Published: (2023-04-01)

The Impact of Coexistence of Smoking and Diabetes on the Coronary Artery Severity and Outcomes following Percutaneous Coronary Intervention: Results from the 1ST Jordanian PCI Registry
by: Mohamad I. Jarrah, et al.
Published: (2020-01-01)

Periinterventional cardiovascular risk and the methods for its reduction in coronary heart disease patients undergoing percutaneous coronary intervention
by: K. A. Nazarova, et al.
Published: (1970-01-01)

The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus
by: To Anh Tan Le, et al.
Published: (2025-06-01)

Association of obesity and LDL subfractions evaluated by body mass index, waist circumference, and diabetes status: the ELSA-Brasil study
by: Eugenio G. Moraes, et al.
Published: (2025-03-01)

LDL estimation with equations and machine learning; variance of LDL and plasma atherogenic index
by: Petros Paplomatas, et al.
Published: (2024-12-01)

Thrombosis prevention in percutaneous coronary interventions
by: V. P. Lupanov, et al.
Published: (2009-08-01)

Long-term Mortality Predictors of Patients Evaluated with Pharmacologic Cardiac Stress SPECT (PS-SPECT) for Suspicion of Chronic Coronary Syndrome
by: Núria Mallofré
Published: (2023-04-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

Comorbidities and Percutaneous Coronary Intervention in Elderly Patients with Acute Coronary Syndrome
by: M. Yu. Gilyarov, et al.
Published: (2021-05-01)

Was there any magnesium?
by: G. N. Sukhodolova
Published: (2022-07-01)

Association of LDL Cholesterol and hs-CRP with Subtypes of Heart Failure in Type 2 Diabetes Mellitus Patients: A Cross-sectional Study
by: Vineetha Naga Lakshmi Giduturi, et al.
Published: (2025-08-01)

A potential marker for increased LDL and hypertriglyceridemia risk
by: K.I.S.N. VAISHNAVI, et al.
Published: (2024-09-01)

Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins
by: Enrique C. Morales-Villegas, et al.
Published: (2011-01-01)

Arterial hypertension and Type 2 diabetes mellitus: any benefits for angiotensin II receptor blockers?
by: V. V. Fomin, et al.
Published: (2007-06-01)

Development of one-year major adverse cardiac events risk index in patients with acute coronary syndrome and diabetes mellitus who underwent percutaneous coronary intervention
by: Mirković Marija, et al.
Published: (2020-01-01)

Prognostic value of systemic immune-Inflammatory index in patients with diabetes mellitus and acute coronary syndrome after percutaneous coronary intervention: a prospective cohort study
by: Leli Zhang, et al.
Published: (2025-08-01)

Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study
by: Zinan Zhao, et al.
Published: (2025-04-01)

Real-World Assessment of the Association Between PCSK9i Adherence and LDL Reduction and Variability in a Chinese Clinical Practice
by: Ye X, et al.
Published: (2025-06-01)

Establishment of a nomogram model for predicting the risk of contrast-induced nephropathy after percutaneous coronary intervention in type 2 diabetics
by: Gu Li, et al.
Published: (2021-01-01)

Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels
by: Hui Ma, et al.
Published: (2025-04-01)

Acute Coronary Syndrome after Percutaneous Coronary Intervention: State of the Problem and Clinical Practice Data
by: I. S. Egorova, et al.
Published: (2023-01-01)

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)